for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Avadel Pharmaceuticals PLC (ADR)

AVDL.OQ

Latest Trade

3.45USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.03

 - 

5.35

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.45
Open
--
Volume
--
3M AVG Volume
9.18
Today's High
--
Today's Low
--
52 Week High
5.35
52 Week Low
1.03
Shares Out (MIL)
37.45
Market Cap (MIL)
134.45
Forward P/E
-3.02
Dividend (Yield %)
--

Next Event

Q3 2019 Avadel Pharmaceuticals PLC Earnings Release

Latest Developments

More

Fresenius Kabi - Announced Immediate Availability In United States Of Phenylephrine Hydrochloride Injection, Usp

Avadel Pharmaceuticals Q2 Loss Per Share $0.23

Avadel Pharmaceuticals Receives New PDUFA Date For AV001 Of December 15, 2019

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Avadel Pharmaceuticals PLC (ADR)

Avadel Pharmaceuticals, PLC is a specialty pharmaceutical company. The Company offers various drug delivery platforms, including Micropump, LiquiTime, Trigger Lock and Medusa. The Company offers its products in various categories, including hospital, including Bloxiverz, Vazculep and Akovaz, and pediatrics, including Karbinal ER, Cefaclor for Oral Suspension, AcipHex Sprinkle and Flexichamber. Bloxiverz is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Vazculep is used to treat clinically hypotension resulting primarily from vasodilation in the setting of anesthesia. Akovaz is indicated to treat clinically hypotension in the setting of anesthesia. Cefaclor is indicated for the treatment of otitis media, lower respiratory infections, pharyngitis and tonsillitis, urinary tract infections, and skin and skin structure infections, caused by susceptible organisms.

Industry

Biotechnology & Drugs

Contact Info

Block 10-1 Blanchardstown Corporate Park

Ballycoolin

+353.1.4851200

https://www.avadel.com/

Executive Leadership

Gregory J. Divis

Chief Executive Officer, Chief Operating Officer, Executive Vice President, Director

Michael F. Kanan

Senior Vice President, Chief Financial Officer

Phillandas T. Thompson

Senior Vice President, General Counsel, Corporate Secretary

Sandra L. Hatten

Senior Vice President - Quality and Regulatory Affairs

Dhiren D'Silva

Vice President - Irish and European Operations

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.2K

2017

0.2K

2018

0.1K

2019(E)

0.0K
EPS (USD)

2016

-1.000

2017

1.610

2018

-0.780

2019(E)

-1.190
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.80
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-54.04
Return on Equity (TTM)
-44.05

Latest News

Latest News

BRIEF-Avadel Pharmaceuticals Reports Q1 Adjusted Loss Per Share $0.34

* Q1 EARNINGS PER SHARE VIEW $-0.27 -- THOMSON REUTERS I/B/E/S

BRIEF-Avadel Pharmaceuticals Announces Promotion Of Gregory Divis To COO

* AVADEL PHARMACEUTICALS ANNOUNCES PROMOTION OF GREGORY J. DIVIS TO CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage:

BRIEF-Avadel Pharmaceuticals Reports Q4 Adjusted Loss Per Share $0.28

* AVADEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS

BRIEF-Avadel Pharmaceuticals Announces Pricing Of $125 Mln 4.50 Pct Exchangeable Senior Notes

* AVADEL PHARMACEUTICALS ANNOUNCES PRICING OF $125.0 MILLION 4.50% EXCHANGEABLE SENIOR NOTES DUE 2023

BRIEF-Avadel Pharmaceuticals Announces Proposed Exchangeable Senior Notes Offering

* AVADEL PHARMACEUTICALS ANNOUNCES PROPOSED EXCHANGEABLE SENIOR NOTES OFFERING

BRIEF-Avadel Pharma Receives Orphan Drug Designation From FDA For FT 218

* AVADEL PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FROM FDA FOR FT 218 FOR THE TREATMENT OF NARCOLEPSY Source text for Eikon: Further company coverage:

BRIEF-Avadel Pharmaceuticals Issues 2018 Corporate Outlook

* REAFFIRMS FY 2017 ADJUSTED EARNINGS PER SHARE VIEW $0.25 TO $0.35

BRIEF-Avadel Pharma Q3 adjusted earnings per share $0.09

* Q3 earnings per share view $-0.02 -- Thomson Reuters I/B/E/S

BRIEF-Avadel Pharmaceuticals Plc says Avadel licensee and Serenity amended exclusivity agreement on Sept 1

* Avadel Pharmaceuticals Plc says on September 1, 2017, Avadel licensee and Serenity amended exclusivity agreement

BRIEF-Avadel Pharmaceuticals Plc ‍enters into a license agreement with Serenity Pharmaceuticals Llc​

* Avadel Pharmaceuticals Plc - entered into a license agreement with Serenity Pharmaceuticals Llc

BRIEF-Avadel Pharmac enters into negotiations with Serenity Pharma for Noctiva

* Avadel Pharmaceuticals enters into exclusive negotiations with Serenity Pharmaceuticals for Noctiva™

BRIEF-Avadel Pharmaceuticals reports Q2 GAAP earnings per share $0.68

* Q2 earnings per share view $0.04 -- Thomson Reuters I/B/E/S

BRIEF-Avadel Pharmaceuticals Q1 GAAP earnings per share $0.59

* Raises FY 2017 adjusted earnings per share view to $0.30 to $0.45

BRIEF-Avadel Pharmaceuticals says plans to reduce headcount in France by About 50 people

* Avadel Pharmaceuticals announces planned reduction of french workforce

BRIEF-Avadel Pharmaceuticals files for non-timely 10-K

* Avadel Pharmaceuticals - expects to file annual report on form 10-K within the extension period of 15 calendar days as provided under rule 12B-25

BRIEF-Avadel Pharmaceuticals reports Q4 EPS $0.11

* Avadel Pharmaceuticals reports fourth quarter and full year 2016 results

BRIEF-Broadfin Capital LLC reports 10.7 pct passive stake in Avadel Pharma - SEC filing

* Broadfin Capital LLC discloses 10.7 percent passive stake in Avadel Pharmaceuticals PLC as of January 3, 2017 - SEC filing Source text - (http://bit.ly/2hXOGX6) Further company coverage:

BRIEF-Avadel Pharmaceuticals provides 2017 guidance and business update

* Avadel Pharmaceuticals provides 2017 guidance and business update

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up